Trial tests new combo to fight heart risk in people with HIV
NCT ID NCT06317051
Summary
This study aims to help people with HIV who are on a common treatment that can increase weight and heart disease risk. It will test if adding the drug dapagliflozin helps with weight loss and heart health more than a placebo. It will also compare two different cholesterol-lowering drug combinations. The trial involves 300 participants and will last 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Melbourne, Victoria, 3084, Australia
-
CART-CRS
Chennai, Tamil Nadu, 600113, India
-
Desmond Tutu Health Foundation
Cape Town, 7925, South Africa
-
HIV-NAT
Bangkok, Thailand
-
Hospital Ramos Mejía
Buenos Aires, Argentina
-
Infectious Diseases Institute, Makerere University
Kampala, Uganda
-
Institute of Human Virology, Nigeria
Abuja, Nigeria
-
St Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
Universiti Malaya Medical Centre
Kuala Lumpur, Malaysia
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.